In contrast, the RAS-MAPK signaling cascade seems to be a very promising target in NF1, at least in benign nerve sheath tumors, low grade gliomas and non-tumor lesions since RAS-MAPK activation is the main pathomechanism. The gene discussed is NF1; the disease is neoplasm.